Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia A

NCT04567511 is registered in ClinicalTrials.gov with Indiana Hemophilia &Thrombosis Center, Inc. as lead sponsor.

NCT NCT04567511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04567511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia A
Lead sponsor
Indiana Hemophilia &Thrombosis Center, Inc.
Phase
Phase 4
Overall status
Recruiting
Start date
July 25, 2022
Completion date
July 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

factor viii deficiency, congenital